Magenta Therapeutics in the spotlight (part III)

FDA setback and 9-month outlook

Following up on our part I and part II posts about Magenta Therapeutics ($MGTA), here we cover today’s Magenta announcement that the FDA has placed a clinical hold on their IND filed in June 2021 for conditioning agent MGTA-117. As a result, MGTA will need to develop an additional bioassay, which will likely result in a delay by about a quarter. We beli…